Bern (ots) - Nicht jeder Kindersitz passt in jedes Auto. Deshalb hat der TCS auch dieses Jahr wieder ...
Oligometastases and Retreatment: New Frontiers in Radiation Therapy
Sunnyvale, California (ots/PRNewswire) - Accuray Conference Focused on Trends in Radiation Oncology
Accuray Incorporated (NASDAQ: ARAY) announced today highlights from their European AERO(TM) (Accuray Exchange in Radiation Oncology) Academy conference hosted in Paris, France on February 5th and 6th.
(Logo: http://photos.prnewswire.com/prnh/20151126/291246LOGO ) (Photo: http://photos.prnewswire.com/prnh/20160108/320402 ) (Photo: http://photos.prnewswire.com/prnh/20160108/320403 )
The conference brought together radiation oncologists and medical physicists from Europe to hear from a panel of renowned European and American experts who specialize in the field of precision radiation therapy, medical physics and radiobiology. This year's theme focused on the use of radiation therapy for the treatment of oligometastases and the retreatment of areas that have previously received radiation. Speakers shared their experiences and discussed new research on the role of these approaches for providing cutting-edge treatments to cancer patients.
"We are proud to provide a forum for experts in radiation therapy to come together every other year to exchange information with their peers and engage in stimulating debates on the challenges facing our field," said Joshua H. Levine, president and chief executive officer at Accuray. "We believe that conferences such as this one, which foster partnerships between industry, clinicians, physicists and scientists will ultimately help shape future clinical decisions, encourage efficiencies and result in improved patient outcomes."
"The AERO educational conference is a great opportunity to exchange with colleagues on clinical improvements and technologies advancements with my peers, to hear about the latest research findings and new trends and most importantly to collaborate with each other to continuously offer innovative cancer treatments to our patients," said Prof. Alain Fourquet, Head of the Radiation Oncology Department, Curie Institute, Paris, France.
About Accuray Exchange in Radiation Oncology (AERO(TM) )
AERO(TM) is a community that fosters the exchange of best practices and discussion of important needs and innovative solutions in the field of precision radiation oncology, by setting a new standard of innovation in patient care. We believe collaboration fuels clinical innovation, so we are dedicated to providing a forum for the exchange of ideas to improve the treatment of cancer and other diseases through use of advanced technologies. Our primary areas of focus are: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) Image-Guided, Intensity-Modulated Radiation Therapy (IG/IMRT) and extended/conventionally fractionated radiation therapy.
Through peer-to-peer sharing of techniques, experiences and challenges, our goal is to facilitate the development of treatment and technical best practices, thus enhancing the future of precision radiation oncology. For more information and to register to the AERO(TM) community, please go to the following link: http://accurayexchange.com/.
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the potential impact and effect of the AERO educational conference and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.